DSPC
Based on 22 publication(s) in Google Scholar
DSPC (1,2-Distearoyl-sn-glycero-3-phosphorylcholine) is a cylindrical-shaped lipid. DSPC is used to synthesize liposomes, and is the lipid component in the lipid nanoparticle (LNP) system.
For research use only. We do not sell to patients.
- Purity : 99.95%
- CAS No.: 816-94-4
- Formula: C44H88NO8P
- Molecular Weight:790.15
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-N0322
Cholesterol (from animal) -
HY-112005
DOPE -
HY-112764
mPEG2000-DMG -
HY-112251
D-Lin-MC3-DMA -
HY-134541
SM-102 -
HY-109506
DPPC -
HY-138170
ALC-0315 -
HY-142979
DSPE-PEG 2000 -
HY-112754A
DOTAP chloride -
HY-113424A
1,2-Dioleoyl-sn-glycero-3-phosphocholine -
HY-138300
ALC-0159 -
HY-N0171A
Beta-Sitosterol (purity>98%)
Publications Citing Use of MedChemExpress (MCE) DSPC
More- Signal Transduct Target Ther. 2025 Mar 24;10(1):101. [Abstract]
- Cell Host Microbe. 2025 Dec 30:S1931-3128(25)00521-9. [Abstract]
- Redox Biol. 2026 May:92:104101. [Abstract]
- Adv Sci (Weinh). 2026 Apr;13(24):e15606. [Abstract]
- Adv Sci (Weinh). 2025 Sep;12(34):e04195. [Abstract]
- Chem Eng J. 2025 Dec 13;527:171849.
- J Control Release. 2026 Jun 18:396:115116. [Abstract]
- J Control Release. 2026 May 23:396:115047. [Abstract]
- J Control Release. 2025 Aug 10:384:113907. [Abstract]
- Int J Nanomedicine. 2025 Oct 22:20:12783-12804. [Abstract]
- Small Methods. 2025 Jun;9(6):e2401712. [Abstract]
- Int J Nanomedicine. 2023 Nov 1:18:6199-6212. [Abstract]
- EMBO Mol Med. 2024 Aug;16(8):1755-1790. [Abstract]
- NPJ Vaccines. 2025 Aug 14;10(1):193. [Abstract]
- Biomacromolecules. 2025 Jun 9;26(6):3563-3575. [Abstract]
- Bioorg Chem. 2026 Apr:171:109526. [Abstract]
- Nanomedicine (Lond). 2026 Mar;21(6):789-801. [Abstract]
- Nanomedicine. 2024 Jun:58:102745. [Abstract]
- Br J Haematol. 2025 Feb;206(2):628-643. [Abstract]
- bioRxiv. 2026 Jul 10.
- bioRxiv. 2026 May 4.
- SSRN. 2025 Oct 29.
Biological Activity
Description
In Vitro
In empty lipid nanoparticle (LNP) systems that do not contain siRNA, DSPC-cholesterol resides in outer layers, whereas in loaded systems a portion of the DSPC-cholesterol is internalised together with siRNA[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 816-94-4
-
Appearance Solid
-
Molecular Weight 790.15
-
Formula C44H88NO8P
-
Color White to off-white
-
SMILES
O=P([O-])(OCC[N+](C)(C)C)OC[C@@H](COC(CCCCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCCCC)=O
-
Synonyms
1,2-Distearoyl-sn-glycero-3-PC; 1,2-Distearoyl-sn-glycero-3-phosphorylcholine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (22)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Intranasal prime-boost RNA vaccination elicits potent T cell response for lung cancer therapy. [Abstract]2025 Mar 24;10(1):101. PMID: 40122855 -
Cell Host Microbe
2025 Dec 30:S1931-3128(25)00521-9. PMID: 41475336 -
Redox Biol
Stromal cell-derived itaconate promotes endometriosis via macrophage NRF2 and lysosomal pH modulation. [Abstract]2026 May:92:104101. PMID: 41780193 -
Adv Sci (Weinh)
An Insulin-Exosome-TNFAIP8 Axis Drives Stromal Fibrosis and Therapeutic Resistance in Pancreatic Cancer. [Abstract]2026 Apr;13(24):e15606. PMID: 41709860 -
Adv Sci (Weinh)
Brachyury-Activated Fucoidan Hydrogel Microspheres Rejuvenate Degenerative Intervertebral Discs Microenvironment. [Abstract]2025 Sep;12(34):e04195. PMID: 40539715 -
-
J Control Release
Reversing immunotherapy resistance in cold tumors by weaponizing pyroptosis with a dual-payload nanotuner. [Abstract]2026 Jun 18:396:115116. PMID: 42314991 -
J Control Release
Antimicrobial peptide-derived lipid nanoparticles enable lung-targeted mRNA therapy for multidrug-resistant bacterial pneumonia. [Abstract]2026 May 23:396:115047. PMID: 42178062 -
J Control Release
Functional lipid nanoparticles for safe delivery of macromolecular antibiotics to gram-negative bacteria. [Abstract]2025 Aug 10:384:113907. PMID: 40451556 -
Int J Nanomedicine
Optimized Lipid Nanoparticle-Mediated mRNA Co-Delivery of SOX5/SOX9 Enables Synergistic Senescence Reversal for Osteoarthritis Therapy. [Abstract]2025 Oct 22:20:12783-12804. PMID: 41146650 -
Small Methods
Cholesterol-Derived Mannosylated Polypeptide-Formed Lipid Nanoparticles for Efficient in Vivo mRNA Delivery. [Abstract]2025 Jun;9(6):e2401712. PMID: 40256901 -
Int J Nanomedicine
IR-820@NBs Combined with MG-132 Enhances the Anti-Hepatocellular Carcinoma Effect of Sonodynamic Therapy. [Abstract]2023 Nov 1:18:6199-6212. PMID: 37933299 -
EMBO Mol Med
LILRB1-HLA-G axis defines a checkpoint driving natural killer cell exhaustion in tuberculosis. [Abstract]2024 Aug;16(8):1755-1790. PMID: 39030302 -
NPJ Vaccines
A self-amplifying mRNA vaccine expressing PRV gD induces robust immunity against virulent mutants. [Abstract]2025 Aug 14;10(1):193. PMID: 40813770 -
Biomacromolecules
Replacing PEG-Lipid with Amphiphilic Polycarbonates in mRNA-Loaded Lipid Nanoparticles: Impact of Polycarbonate Structure on Physicochemical and Transfection Properties. [Abstract]2025 Jun 9;26(6):3563-3575. PMID: 40347133 -
Bioorg Chem
Design and synthesis of novel ionizable lipids enables highly efficient mRNA delivery via lipid nanoparticles. [Abstract]2026 Apr:171:109526. PMID: 41621179 -
Nanomedicine (Lond)
Precise atorvastatin delivery by cardiac homing peptide functionalized nanoliposomes for myocardial damage repair after myocardial infarction. [Abstract]2026 Mar;21(6):789-801. PMID: 41660754 -
Nanomedicine
Quantitative analysis of mRNA-lipid nanoparticle stability in human plasma and serum by size-exclusion chromatography coupled with dual-angle light scattering. [Abstract]2024 Jun:58:102745. PMID: 38499167 -
Br J Haematol
mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells. [Abstract]2025 Feb;206(2):628-643. PMID: 39761676 -
-
-
Solvent & Solubility
In Vitro:
Ethanol : 12.5 mg/mL (15.82 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.25 mg/mL (1.58 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: 1.25 mg/mL (1.58 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 1.25 mg/mL (1.58 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 1.2656 mL | 6.3279 mL | 12.6558 mL | 31.6396 mL |
| 5 mM | 0.2531 mL | 1.2656 mL | 2.5312 mL | 6.3279 mL | |
| 10 mM | 0.1266 mL | 0.6328 mL | 1.2656 mL | 3.1640 mL | |
| 15 mM | 0.0844 mL | 0.4219 mL | 0.8437 mL | 2.1093 mL |
DSPC Related Classifications
HY-W040193 Related Classifications
Powered by Bioz